Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

被引:51
作者
Kim, Mikyung
Qiao, Zhisong
Yu, Jessica
Montefiori, David
Reinherz, Ellis L.
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Lab Immunobiol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Duke Univ, Ctr Med, Dept Surg, Durham, NC 27710 USA
关键词
HIV; gp41; MPER; immunogen; immunodominance; neutralizing antibody; 2F5; 4E10; virus-like particle; vaccine;
D O I
10.1016/j.vaccine.2006.09.071
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The conserved membrane proximal external region (MPER) of the ectodomain of human immunodeficiency virus type I (HIV-1) gp41 is the target of two broadly neutralizing antibodies, 2F5 and 4E10. However, no neutralizing antibodies have been elicited against immunogens bearing these epitopes. Given that structural and biochemical studies suggest that the lipid membrane of the virion is involved in their proper configuration, HIV-1 gp41 derivatives in a pre-fusion state were expressed on the surface of immature virus like particles (VLP) derived from Sf9 cells. Guinea pigs were immunized with three doses of VLPs or Sf9 cells presenting gp41 derivatives with or without E. coli heat-labile enterotoxin (LT) as an adjuvant. While immune sera contained high titer anti-VLP antibodies, the specific anti-gp41 antibody responses were low with no neutralizing antibodies detected. An explanation for this absence may be the low level of gp41 expression relative to the many other proteins derived from host cells which are incorporated onto the VLP surface. In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance. (C) 2006 Elsevier Ltd. All fights reserved.
引用
收藏
页码:5102 / 5114
页数:13
相关论文
共 87 条
  • [1] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [2] RECOMBINANT HUMAN FAB FRAGMENTS NEUTRALIZE HUMAN TYPE-1 IMMUNODEFICIENCY VIRUS INVITRO
    BARBAS, CF
    BJORLING, E
    CHIODI, F
    DUNLOP, N
    CABABA, D
    JONES, TM
    ZEBEDEE, SL
    PERSSON, MAA
    NARA, PL
    NORRBY, E
    BURTON, DR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) : 9339 - 9343
  • [3] Structural analysis of the epitope of the Anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion
    Barbato, G
    Bianchi, E
    Ingallinella, P
    Hurni, WH
    Miller, MD
    Cilibertol, G
    Cortese, R
    Bazzo, R
    Shiver, JW
    Pessi, A
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 330 (05) : 1101 - 1115
  • [4] The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    Barnet, SW
    Lu, S
    Srivastava, I
    Cherpelis, S
    Gettie, A
    Blanchard, J
    Wang, S
    Mboudjeka, I
    Leung, L
    Lian, Y
    Fong, A
    Buckner, C
    Ly, A
    Hilt, S
    Ulmer, J
    Wild, CT
    Mascola, JR
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (12) : 5526 - 5540
  • [5] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    Binley, JA
    Wrin, T
    Korber, B
    Zwick, MB
    Wang, M
    Chappey, C
    Stiegler, G
    Kunert, R
    Zolla-Pazner, S
    Katinger, H
    Petropoulos, CJ
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (23) : 13232 - 13252
  • [6] Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding
    Binley, JM
    Ditzel, HJ
    Barbas, CF
    Sullivan, N
    Sodroski, J
    Parren, PWHI
    Burton, DR
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (10) : 911 - 924
  • [7] A monomeric 310-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41
    Biron, Z
    Khare, S
    Samson, AO
    Hayek, Y
    Naider, F
    Anglister, J
    [J]. BIOCHEMISTRY, 2002, 41 (42) : 12687 - 12696
  • [8] Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody
    Brunel, FM
    Zwick, MB
    Cardoso, RMF
    Nelson, JD
    Wilson, IA
    Burton, DR
    Dawson, PE
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (04) : 1680 - 1687
  • [9] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [10] Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41
    Caffrey, M
    Cai, ML
    Kaufman, J
    Stahl, SJ
    Wingfield, PT
    Covell, DG
    Gronenborn, AM
    Clore, GM
    [J]. EMBO JOURNAL, 1998, 17 (16) : 4572 - 4584